Abstract | BACKGROUND: OBJECTIVES: To study the ability of antiviral drugs to eradicate such infection in vitro to evalaute their potential in the treatments of these patients. STUDY DESIGN: We set out to evaluate several licensed or clinically tested drugs which have shown some anti-enterovirus activity in previous studies for their ability to cure persistent infection established by two different coxsackievirus B1 strains in a pancreatic cell line (PANC-1 cells). RESULTS: CONCLUSIONS: The identified drugs are feasible candidates for clinical trials among patients with persistent coxsackievirus B infections or chronic enterovirus-associated diseases.
|
Authors | Anni Honkimaa, Amir-Babak Sioofy-Khojine, Sami Oikarinen, Antoine Bertin, Didier Hober, Heikki Hyöty |
Journal | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
(J Clin Virol)
Vol. 128
Pg. 104334
(07 2020)
ISSN: 1873-5967 [Electronic] Netherlands |
PMID | 32450550
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2020 Elsevier B.V. All rights reserved. |
Chemical References |
|
Topics |
- A549 Cells
- Antiviral Agents
(pharmacology)
- Cell Line, Tumor
- Cytopathogenic Effect, Viral
(drug effects)
- Drug Discovery
- Enterovirus B, Human
(drug effects, physiology)
- Humans
- Microbial Viability
(drug effects)
- Models, Biological
- Pancreatic Neoplasms
- Phenotype
- Virus Replication
(drug effects)
|